Regents of University of Michigan v. Novartis Pharmaceuticals Corporation
Opinion
Trial Court Opinion
UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF CALIFORNIA 6 REGENTS OF UNIVERSITY OF Case No. 22-cv-04913-AMO MICHIGAN, et al., 8 Plaintiffs, ORDER GRANTING STAY 9 v. Re: Dkt. No. 81
NOVARTIS PHARMACEUTICALS
CORPORATION, Defendant. 12 Before the Court is Defendant Novartis Pharmaceuticals Corporation’s motion to stay the case pending inter partes review (“IPR”). The matter is fully briefed and suitable for decision without oral argument. Accordingly, the hearing set for February 22, 2024, is VACATED. See Civil L.R. 7-6. Having read the parties’ papers and carefully considered their arguments and the relevant legal authority, and good cause appearing, the Court hereby GRANTS the motion. I. BACKGROUND Plaintiffs filed their complaint on August 29, 2022, asserting that Novartis’s Entresto product infringes claims 10, 11, 16, and 18 of the expired U.S. Patent No. 10,633,344 (the “‘344 patent”). ECF 1. Novartis filed its answer on November 21, 2022. ECF 42. The Court held the Initial Case Management…